Human Wharton’s Jelly Mesenchymal Stem Cell Secretome Display Significant Antiproliferative Effect on K562 Leukemia Cells
Objective: Leukemia accounts for one-third of all cancers diagnosed in children (ages 0 to 14 years) against existence of multiple current treatments such as chemotherapy and hematopoietic stem cell transplantation, mortality is high among patients. On the other hand sever adverse effects of current therapeutic plans remains a challenge. Accordingly research toward finding new therapeutic strategies has been continuing. One of the recently interesting areas in cancer research is mesenchymal stem cell therapy. However existing results show requirement for further experiments. Umbilical cord as a newly used source of mesenchymal stem cell should be investigated more before entering clinical cell therapy plans. In this regard we examined the effect of human Wharton’s jelly mesenchymal stem cell secretome on K562 leukemia cells. Materials and Methods: MSCs were first isolated from human umbilical cord, then characterized with respect to their morphology, surface antigenicity and mesodermal lineage differentiation potential. MSC secretome was collected and applied on K562 cells. BrdU proliferation assay and Annexin V-PI staining was used for K562 proliferation and apoptosis evaluations. Results: Results displayed significant antiproliferative effect of Wharton’s jelly MSC secretome on K562 leukemia cells. Conclusion: MSC itself or even MSC secretome can be used as an anticancer agent in leukemia patients.